• In recent months, FIGS has reported weaker growth in active customers alongside multi-year pressure on earnings per share, pointing to softer demand and declining profitability. These trends, combined with only moderate free cash flow margins, have raised questions about how much cash the business can reinvest or return to shareholders.
• We’ll now examine how slowing active customer growth and softer profitability trends may influence FIGS’ previously optimistic investment narrative.
• We’ll now examine how slowing active customer growth and softer profitability trends may influence FIGS’ previously optimistic investment narrative.

Find 55 companies with promising cash flow potential yet trading below their fair value.

FIGS Investment Narrative Recap

To own FIGS, you need to believe its direct to consumer brand in medical apparel can keep converting healthcare professionals into loyal, repeat customers. The recent signs of weaker active customer growth and pressure on earnings per share highlight that the key short term catalyst renewed customer momentum now sits uncomfortably close to the biggest risk that softer demand and only moderate free cash flow constrain reinvestment and marketing firepower.

In that context, FIGS’ ongoing share repurchase program, with more than 10.4 million shares bought back for about US$56.8 million to date, is especially relevant. While buybacks can support per share metrics, they also reduce balance sheet flexibility if demand weakness or margin pressures persist, which matters when the growth story depends on funding new products, international markets and stronger engagement with existing customers.

Yet beneath the strong brand, the risk that slowing customer growth and earnings pressure could limit FIGS’ ability to keep funding its own story is something investors should be aware of...

FIGS' narrative projects $862.6 million revenue and $77.4 million earnings by 2029.

Uncover how FIGS' forecasts yield a $17.62 fair value, a 65% upside to its current price.

Exploring Other Perspectives

Some of the most pessimistic analysts were already assuming only about 8 percent annual revenue growth to roughly US$838.0 million and earnings of around US$76.0 million, so the latest softness in active customers and profitability could make you question whether even those cautious expectations and concerns about reliance on a slowing core market are still realistic or need to be revisited.

Explore 5 other fair value estimates on FIGS - why the stock might be worth just $11.61!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your FIGS research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free FIGS research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate FIGS' overall financial health at a glance.

Searching For A Fresh Perspective?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.